MarketBeat Instant News Alerts 2 hours agoWells Fargo & Company Raises Halozyme Therapeutics (NASDAQ:HALO) Price Target to $65.00MarketBeatWells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday.NASDAQ:HALORead Wells Fargo & Company Raises Halozyme Therapeutics (NASDAQ:HALO) Price Target to $65.002 hours agoWells Fargo & Company Raises Brookfield Asset Management (NYSE:BAM) Price Target to $54.00MarketBeatWells Fargo & Company lifted their price objective on shares of Brookfield Asset Management from $48.00 to $54.00 and gave the stock an "underweight" rating in a report on Wednesday.NYSE:BAMRead Wells Fargo & Company Raises Brookfield Asset Management (NYSE:BAM) Price Target to $54.002 hours agoWells Fargo & Company Issues Positive Forecast for Corebridge Financial (NYSE:CRBG) Stock PriceMarketBeatWells Fargo & Company upped their price target on shares of Corebridge Financial from $35.00 to $37.00 and gave the company an "overweight" rating in a report on Wednesday.NYSE:CRBGRead Wells Fargo & Company Issues Positive Forecast for Corebridge Financial (NYSE:CRBG) Stock Price2 hours agoProgressive (NYSE:PGR) Price Target Raised to $328.00 at Wells Fargo & CompanyMarketBeatWells Fargo & Company lifted their price target on shares of Progressive from $324.00 to $328.00 and gave the stock an "overweight" rating in a research report on Wednesday.NYSE:PGRRead Progressive (NYSE:PGR) Price Target Raised to $328.00 at Wells Fargo & Company2 hours agoWells Fargo & Company Has Lowered Expectations for Omnicell (NASDAQ:OMCL) Stock PriceMarketBeatWells Fargo & Company cut their price target on shares of Omnicell from $38.00 to $31.00 and set an "equal weight" rating for the company in a report on Wednesday.NASDAQ:OMCLRead Wells Fargo & Company Has Lowered Expectations for Omnicell (NASDAQ:OMCL) Stock Price2 hours agoSarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $81.00 at Cantor FitzgeraldMarketBeatCantor Fitzgerald decreased their price objective on Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating for the company in a research report on Wednesday.NASDAQ:SRPTRead Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $81.00 at Cantor Fitzgerald Trending News1Cantor Equity Partners, Inc. Class A Ordinary Shares (NASDAQ:CEP) Sees Strong Trading Volume - Still a Buy?2Raymond James Financial Inc. Acquires New Holdings in QuantumScape Co. (NYSE:QS)3ArrowMark Colorado Holdings LLC Increases Stock Position in BlackBerry Limited (NYSE:BB)4131,600 Shares in SoundHound AI, Inc. (NASDAQ:SOUN) Bought by Bulltick Wealth Management LLC5Wolfspeed (NYSE:WOLF) Shares Gap Up - Time to Buy?6Baker BROS. Advisors LP Purchases 464,936 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)7Raymond James Financial Inc. Acquires Shares of 63,961 AST SpaceMobile, Inc. (NASDAQ:ASTS)8Capstone Investment Advisors LLC Sells 32,050 Shares of Alibaba Group Holding Limited (NYSE:BABA) All MarketBeat Instant News Alerts Latest News Trending News Sort By Last 24 Hours Last 3 Days Last 7 Days Last 14 Days Last 30 Days Last 90 Days All Time Time Frame All Alerts Analyst Congressional Trades Consensus Dividend Earnings Earnings Preview Estimates Guidance Insider Trade Lockup Expiration Options Price SEC Filing Stock List Stock Split Alert Type Keywords 2 hours agoWells Fargo & Company Issues Pessimistic Forecast for Masimo (NASDAQ:MASI) Stock PriceMarketBeatNASDAQ:MASIRead Wells Fargo & Company Issues Pessimistic Forecast for Masimo (NASDAQ:MASI) Stock Price2 hours agoCorbus Pharmaceuticals (NASDAQ:CRBP) Given New $56.00 Price Target at OppenheimerMarketBeatNASDAQ:CRBPRead Corbus Pharmaceuticals (NASDAQ:CRBP) Given New $56.00 Price Target at Oppenheimer2 hours agoWells Fargo & Company Lowers Arcus Biosciences (NYSE:RCUS) Price Target to $26.00MarketBeatNYSE:RCUSRead Wells Fargo & Company Lowers Arcus Biosciences (NYSE:RCUS) Price Target to $26.002 hours agoRigel Pharmaceuticals (NASDAQ:RIGL) Price Target Raised to $23.00MarketBeatNASDAQ:RIGLRead Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target Raised to $23.002 hours agoBeam Therapeutics (NASDAQ:BEAM) Price Target Cut to $70.00 by Analysts at Wells Fargo & CompanyMarketBeatNASDAQ:BEAMRead Beam Therapeutics (NASDAQ:BEAM) Price Target Cut to $70.00 by Analysts at Wells Fargo & Company2 hours agoCantor Fitzgerald Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $112.00MarketBeatNASDAQ:PTCTRead Cantor Fitzgerald Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $112.002 hours agoWells Fargo & Company Issues Positive Forecast for UL Solutions (NYSE:ULS) Stock PriceMarketBeatNYSE:ULSRead Wells Fargo & Company Issues Positive Forecast for UL Solutions (NYSE:ULS) Stock Price2 hours agoOppenheimer Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $123.00MarketBeatNASDAQ:SRPTRead Oppenheimer Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $123.002 hours agoBall (NYSE:BALL) Price Target Raised to $50.00 at Wells Fargo & CompanyMarketBeatNYSE:BALLRead Ball (NYSE:BALL) Price Target Raised to $50.00 at Wells Fargo & Company2 hours agoXometry (NASDAQ:XMTR) Given New $21.00 Price Target at Cantor FitzgeraldMarketBeatNASDAQ:XMTRRead Xometry (NASDAQ:XMTR) Given New $21.00 Price Target at Cantor Fitzgerald2 hours agoWells Fargo & Company Boosts Lear (NYSE:LEA) Price Target to $89.00MarketBeatNYSE:LEARead Wells Fargo & Company Boosts Lear (NYSE:LEA) Price Target to $89.002 hours agoOppenheimer Forecasts Strong Price Appreciation for Porch Group (NASDAQ:PRCH) StockMarketBeatNASDAQ:PRCHRead Oppenheimer Forecasts Strong Price Appreciation for Porch Group (NASDAQ:PRCH) Stock2 hours agoWells Fargo & Company Increases Avient (NYSE:AVNT) Price Target to $42.00MarketBeatNYSE:AVNTRead Wells Fargo & Company Increases Avient (NYSE:AVNT) Price Target to $42.002 hours agoCelanese (NYSE:CE) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysMarketBeatNYSE:CERead Celanese (NYSE:CE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says2 hours agoIngevity (NYSE:NGVT) Given New $38.00 Price Target at Wells Fargo & CompanyMarketBeatNYSE:NGVTRead Ingevity (NYSE:NGVT) Given New $38.00 Price Target at Wells Fargo & Company2 hours agoIngevity (NYSE:NGVT) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysMarketBeatNYSE:NGVTRead Ingevity (NYSE:NGVT) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says2 hours agoWells Fargo & Company Has Lowered Expectations for Flywire (NASDAQ:FLYW) Stock PriceMarketBeatNASDAQ:FLYWRead Wells Fargo & Company Has Lowered Expectations for Flywire (NASDAQ:FLYW) Stock Price2 hours agoFlywire (NASDAQ:FLYW) Price Target Lowered to $13.00 at Wells Fargo & CompanyMarketBeatNASDAQ:FLYWRead Flywire (NASDAQ:FLYW) Price Target Lowered to $13.00 at Wells Fargo & Company2 hours agoElectronic Arts (NASDAQ:EA) Price Target Raised to $185.00MarketBeatNASDAQ:EARead Electronic Arts (NASDAQ:EA) Price Target Raised to $185.002 hours agoElectronic Arts (NASDAQ:EA) Given New $185.00 Price Target at OppenheimerMarketBeatNASDAQ:EARead Electronic Arts (NASDAQ:EA) Given New $185.00 Price Target at Oppenheimer2 hours agoPaymentus (NYSE:PAY) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysMarketBeatNYSE:PAYRead Paymentus (NYSE:PAY) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says2 hours agoWells Fargo & Company Has Lowered Expectations for DoorDash (NASDAQ:DASH) Stock PriceMarketBeatNASDAQ:DASHRead Wells Fargo & Company Has Lowered Expectations for DoorDash (NASDAQ:DASH) Stock Price2 hours agoWells Fargo & Company Cuts Datadog (NASDAQ:DDOG) Price Target to $115.00MarketBeatNASDAQ:DDOGRead Wells Fargo & Company Cuts Datadog (NASDAQ:DDOG) Price Target to $115.002 hours agoPiper Sandler Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock PriceMarketBeatNASDAQ:SRPTRead Piper Sandler Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Featured Articles and OffersRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsBy Ryan Hasson | May 5, 2025View Rocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsWall Street just bet big on Gold…From ProsperityPub(Ad)View Wall Street just bet big on Gold…3 Mid-Cap Medical Stocks Outperforming the MarketBy Ryan Hasson | May 6, 2025View 3 Mid-Cap Medical Stocks Outperforming the MarketWhy Wells Fargo Is Buying $40 Billion of Its Own StockBy Gabriel Osorio-Mazilli | May 6, 2025View Why Wells Fargo Is Buying $40 Billion of Its Own StockUPS Stock Forecast: Rebound Underway for United Parcel Service?By Thomas Hughes | May 4, 2025View UPS Stock Forecast: Rebound Underway for United Parcel Service?Virtually Limitless Energy?From Stansberry Research(Ad)View Virtually Limitless Energy?Cantor Equity Partners, Inc. Class A Ordinary Shares (NASDAQ:CEP) Sees Strong Trading Volume - Still a Buy?By MarketBeat | May 8, 2025View Cantor Equity Partners, Inc. Class A Ordinary Shares (NASDAQ:CEP) Sees Strong Trading Volume - Still a Buy?Raymond James Financial Inc. Acquires New Holdings in QuantumScape Co. (NYSE:QS)By MarketBeat | May 8, 2025View Raymond James Financial Inc. Acquires New Holdings in QuantumScape Co. (NYSE:QS) Sector NewsAerospace NewsArtificial Intelligence NewsAutomotive NewsConsumer Product NewsEnergy NewsFinancial Services NewsHealthcare NewsIndustrial NewsMedia NewsManufacturing NewsTechnology NewsTransportation NewsRetail News Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
